Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab intervention and diet evaluation for pouchitis
2025-521683-35-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of guselkumab in pouchitis (2 arms), sponsored by UZ Leuven. Primary endpoint: Clinical remission at week 16. Planned start Mar 2026; status: authorised.
02
Drugs
guselkumab
03
Conditions
pouchitis
Beyond the preview
Go deeper on 2025-521683-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521683-35-00.